Arylamine N-acetyltransferase-1 (NAT1) has been associated with disorders involving folate metabolism, such as spina bifida, as well as numerous human cancers. As a result, the transcriptional and post-transcriptional regulation of NAT1 activity has been extensively studied.
Introduction
Arylamine N-acetyltransferase-1 (NAT1) is a phase II enzyme that acetylates a range of arylamine and hydrazine substrates (Minchin et al., 1992; Hein et al., 1993) . NAT1 is widely distributed in the body and has been associated with disorders involving folate metabolism, such as spina bifida and cleft palate (Jensen et al., 2006; Erickson et al., 2008) , as well as susceptibility to various cancers (Hein et al., 2000; Butcher et al., 2002) . As a result, the regulation of NAT1 activity has been studied in detail (Butcher et al., 2008) . The NAT1 gene consists of 9 exons, encompassing over 52 kb (Boukouvala and Sim, 2005; Butcher et al., 2005) on chromosome 8. Exon 9 contains the entire 870 bp open reading frame (ORF), while various splicing of the first 8 exons make up the 5'-untranslated region (UTR). NAT1 transcription is driven by two alternative promoters (Minchin et al., 2007) . The distal NAT1 promoter, NATa, drives the expression of Type I transcripts that begin with exon 1. These transcripts show tissuespecific expression (Barker et al., 2006) . A number of putative transcription factor binding-sites were observed within the NATa promoter region (Barker et al., 2006) . The proximal or constitutive NAT1 promoter, NATb, drives the expression of Type II transcripts that begin with exon 4. NATb is responsible for the expression of most NAT1 mRNA and transcripts arising from this promoter have been detected in almost all tissues and human cell-lines examined (Butcher et al., 2005; Barker et al., 2006; Husain et al., 2007) . Thus, NATb most likely accounts for the ubiquitous expression of NAT1 in human tissues and cell-lines. NATb is also androgenresponsive through an androgen-dependent heat shock factor binding site located 776 base pairs upstream of the transcription start site Butcher et al., 2007) .
NAT1 is responsible for the acetylation of the folate catabolite p-aminobenzoylglutamate (Minchin, 1995; Sim and Ward, 1995) . The importance of this metabolite is not well understood, DMD # 36202 This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 24, 2010 as DOI: 10.1124 at ASPET Journals on June 23, 2017 dmd.aspetjournals.org Downloaded from particularly as mice lacking the ability to acetylate p-aminobenzoylglutamate are generally aphenotypic (Cornish et al., 2003; Sugamori et al., 2003) . However, NAT1 has been shown to alter the growth kinetics of non-transformed breast cells (Adam et al., 2003) and it also appears to be necessary for cell invasion in the breast cancer cell-line MDA-MB-231 (Tiang et al.) .
These observations suggest the enzyme may have a role in addition to xenobiotic metabolism. In the gastrointestinal tract, NAT1 activity is relatively constant from the duodenum to the colon but, at the level of the crypts, greater variation has been reported (Hickman et al., 1998) . The NAT1 protein is almost absent in the proliferating cells located at the base of the crypt but is highly expressed in the differentiated non-proliferating epithelial cells at the tips of the villus.
Thus, NAT1 may be up-regulated as cells enter senescence or as they express a more differentiated phenotype. In the course of our studies into the regulation of NAT1 activity, we observed a marked increase in NAT1 in cells following treatment with the differentiating agents sodium butyrate and trichostatin A (TSA), but not with retinoic acid. Both sodium butyrate and TSA are non-specific histone deacetylase (HDAC) inhibitors. HDACs, along with the histone acetyltransferases, regulate the acetylation status of histones. Histone acetyltransferases add acetyl groups to lysine residues of proteins, while HDACs remove these acetyl groups. Posttranslational acetylation of core histones associated with DNA influences chromatin structure and is central to the regulation of transcription (Senese et al., 2007; Smith and Workman, 2009 ).
Interestingly, the major Class I histones are down-regulated during maturation of intestinal cells along the crypt-villus axis (Wilson et al., 2006) .
Here, we report that the HDAC inhibitor TSA up-regulates NAT1 expression through a conserved Sp1 site previously reported to be essential for NAT1 expression from the NATb promoter (Husain et al., 2007) . HDAC inhibitors have entered clinical trials for the treatment of a
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This article has not been copyedited and formatted. The final version may differ from this version. supplemented with 5% fetal bovine serum (FBS) and penicillin/streptomycin. Human MCF-7 cells were cultured in DMEM supplemented with 5% FBS and penicillin/streptomycin (Invitrogen, VIC, Australia). All cell-lines were maintained at 37°C in a humidified atmosphere of 5% CO 2 in air. Cells were treated with up to 0.5 μM TSA (Sigma) or vehicle (DMSO) for up to 24 hr at 37°C. Actinomycin D (Sigma, MO) was used at a final concentration of 5μg/ml. NAT1 activity assay. Cells were washed with PBS, resuspended in NAT1 assay buffer (20 mM Tris, pH 7.4, 1 mM EDTA, 1 mM dithiothreitol) and lysed by sonication. Cell lysates were then immediately assayed for NAT1 activity by HPLC using p-aminobenzoic acid as substrate as described previously (Butcher et al., 2000) .
Identification of NAT1 transcripts by reverse transcription-PCR (RT-PCR). Total
RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's instructions.
Approximately 5 μ g total RNA was resuspended in RNAse-free water and reverse transcribed using Superscript II Reverse Transcriptase (Invitrogen) and oligo(dT) 15 primer (Promega, NSW, Australia) according to the manufacturer's instructions. First-strand cDNA from cells grown in the presence or absence of 0.5 μM TSA was amplified by PCR using specific primers designed to detect NATa or NATb transcripts (see Table 1 This article has not been copyedited and formatted. The final version may differ from this version. 
Electrophoretic mobility shift assay (EMSA). Nuclear extracts from HeLa cells (~ 5 × 1 0
EMSAs were performed as described previously (Butcher and Minchin, 2010) . Briefly, 1 × 10 5 d.p.m. of 32 P-labeled oligonucleotides probes (see Table 1 ) and 2 μ g of nuclear extracts
were incubated at room temperature for 30 min in binding buffer (4% Ficoll 400, 50 mM KCl, 20 mM HEPES, pH 7.9, 2.5 mM DTT, 20
analysis, a 100-fold molar excess of unlabelled oligonucleotides was used. For supershift assays, 2 μ g of Sp1 antibody (sc-44221, Santa Cruz) was added before the 30 min incubation. Samples were then resolved on 5% non-denaturing polyacrylamide gels (120 V for 45 min) at 4°C. Gels were dried at 70°C for 40 min, placed on a phosphorimage screen overnight and then analysed using a BAS-5000 phosphorimager (Berthold, NSW, Australia).
Chromatin immunoprecipitation (ChIP) assays. HeLa cells (~2 × 10 6 ) treated with either 0.5 μM TSA or vehicle for 6 hr were washed once with PBS and cross-linked in 1.5%
formaldehyde (in PBS) for 15 min at room temperature. Cells were washed once in cold PBS, lysed on ice in lysis buffer (10 mM EDTA, 50 mM Tris/HCl, pH 8.0, 1% SDS, 0.5 mM PMSF, 2 µg/ml leupeptin, 2 µg/ml pepstatin A) and sonicated on ice (3 × 15 s bursts) to fragment the chromatin to an average length of approximately 600 bp. Lysates were then centrifuged at 4°C
for 15 min at 14,000 × g. A 20 μ l aliquot of each supernatant was diluted up to 50 μ l in dilution buffer (2 mM EDTA, 150 mM NaCl, 20 mM Tris/HCl, pH 8.0, 1% Triton X-100, 0.5 mM PMSF, 2 µg/ml leupeptin, 2 µg/ml pepstatin A), and stored for use as positive controls for PCR.
The remaining supernatants were diluted 1:10 in dilution buffer and divided into 3 tubes of equal volume. Chromatin-protein complexes were immunoprecipitated with approximately 2 μ g of either Sp1 antibody (sc-44221, Santa Cruz), acetyl-histone H4 (Lys8) antibody (2594S, Genesearch, QLD, Australia) or purified goat-IgG overnight at 4°C. After equilibration in dilution buffer, 50 μ l of Protein-A sepharose beads (GE Healthcare, NSW, Australia) were added
This article has not been copyedited and formatted. The final version may differ from this version. to each sample and rotated at 4°C for 2 hr. After extensive washing, chromatin-protein complexes were eluted in 100 μ l elution buffer (0.1 M NaHCO 3 and 1% SDS) at room temperature for 10 min. Samples, including those used as positive PCR controls, were heated at 65°C overnight to reverse cross-linking. DNA was then purified using MinElute PCR purification spin columns (Qiagen, VIC, Australia). PCR was performed on purified DNA using primers flanking the NATb promoter region containing the Sp1 binding site (186 bp fragment) or GAPDH as a negative control (180 bp fragment) (see Table 1 for primer sequences) Reactions contained Thermopol buffer (New England Biolabs), 6.25 pmol of each primer, 0.25 μΜ dNTPs, 0.2 U Taq DNA polymerase (New England Biolabs) and 3 μ l DNA in a final volume of 25 µl.
Samples were amplified using the following conditions; initial denaturation at 95°C for 3 min, followed by 45 cycles of denaturation at 95°C for 15 s, annealing at 57°C (NATb) or 51°C
(GAPDH) for 15 s and extension at 72°C for 20 s. PCR products were then separated on 2% agarose gels and identified according to size.
Data analysis and statistics. Data are expressed as mean ± standard error (SE).
Statistical comparisons between different treatments were assessed by Student's t-tests or oneway analysis of variance (ANOVA) using significance at p < 0.05. NATb mRNA half-life was estimated by fitting a linear regression to the data using Prism 4 (GraphPad Software Inc., CA).
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Results
NAT1 activity is induced by TSA in a cell density-dependent manner. TSA significantly increased NAT1 enzyme activity in several cell-lines following treatment for 24 hr (Fig. 1A) . The highest increase (3.2-fold) was seen in HeLa cells, a cervical adenocarcinoma.
Induction was not dependent on the basal level of NAT1 expression, which was 4.2 ± 0.2, 6.7 ± 0.1, 22.9 ± 0.7 and 38.9 ± 1.6 nmol/min/mg protein for HeLa, HepG2 (liver), and ZR-75-1 (breast) cells, respectively. The effect of TSA on gene expression has been reported to be dependent on cell density (Gray and Ekstrom, 1998). NAT1 activity was determined in
HeLa cells cultured at 40%, 80% and 100% confluence, both with and without TSA treatment.
Induction of NAT1 by TSA was highest in the least confluent cells (4.1-fold) and decreased to less than 1.5-fold in 100% confluent cells (Fig. 1B) .
TSA up-regulated NATb promoter activity. To determine if TSA up-regulated NATa or NATb promoter activity in HeLa cells, specific forward primers located in exon 3 (NATa transcripts) or exon 4 (NATb transcripts) were used with a common reverse primer located in the protein coding region to amplify cDNA following TSA treatment ( Fig. 2A) . NATb transcripts were present in both vehicle-and TSA-treated cells, whereas NATa transcripts were not detected in either group. Human liver tissue, which constitutively expresses NATa transcripts (Barker et al., 2006) , was used as a positive control for the detection of transcripts derived from NATa. This result suggested that TSA had its effect via the NATb promoter. Quantification of mRNA derived from NATb by qPCR showed that TSA treatment caused a 25-fold increase in NAT1 mRNA (Fig. 2B ).
HDAC inhibitors not only affect gene transcription by altering the interaction of histones with DNA, but they also affect mRNA stability (Spange et al., 2009) . To determine whether TSA
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This article has not been copyedited and formatted. The final version may differ from this version. altered the stability of NAT1 mRNA, HeLa cells were treated with TSA in the presence of the transcriptional inhibitor actinomycin D (Fig. 2C ). In the absence of TSA, the slope of the mRNA decay curve was -0.78 ± 0.09 hr -1 whereas, in the presence of the HDAC inhibitor, it was -0.46 ± 0.02 hr -1 . This suggests that TSA had a small, albeit significant, effect on NAT1 mRNA stability, but this effect was unlikely to account for the 25-fold increase in NAT1 mRNA observed following treatment.
Identification of the TSA responsive region in NATb. A series of NAT1 promoter reporter constructs (Butcher et al., 2007) was used to identify the TSA responsive region within the NATb promoter. The longest promoter sequence, a 3657 bp fragment of NATb immediately upstream of exon 4 (Butcher et al., 2007) , was induced by TSA approximately 18-fold (Fig. 3A) .
Induction was seen with all constructs down to a promoter length of 34 bp. This final sequence is shown in Fig 3B along While the wild-type construct showed TSA induction of approximately 45-fold, induction of the mutant construct was less than 5-fold (Fig. 4A) , indicating that this region of the NATb promoter was critical for TSA activity.
Next, electromobility shift assays (EMSA) were performed to identify whether Sp1 bound to the putative Sp1 binding sequence. Nuclear extracts from DMSO-and TSA-treated
This article has not been copyedited and formatted. The final version may differ from this version. HeLa cells were incubated with 32 P-labelled oligonucleotide probe spanning the Sp1 site in NATb (Fig. 4B) . Three complexes were observed, all of which were competed out with excess unlabelled probe. However, only the upper band (Fig. 4B, arrow) was not affected by excess probe containing mutations in the Sp1 site (Fig. 4B, lane 4) , suggesting this band represented Sp1 binding. The presence of Sp1 was confirmed by a supershift using a Sp1-specific antibody (Fig. 4B, lane 8) . When the probe was incubated with nuclear extracts from cells treated with TSA, a more intense band was observed, consistent with an increase in Sp1 binding (Fig. 4, lane   7 ). However, this increase was not due to an overall increase in Sp1 expression. Western blot analysis showed no change in the level of transcription factor over 24 hr of treatment with TSA ( Fig. 4C ).
Sp1 bound to the NATb promoter in vivo.
Because EMSAs assess the binding of nuclear proteins to DNA probes, they may not necessarily represent protein binding to DNA elements in the context of the nuclear chromatin. To address this, a ChIP assay was performed.
DNA from DMSO-and TSA-treated HeLa cells was immunoprecipitated with anti-Sp1 antibody and then amplified using primers that spanned the Sp1 binding site. Sp1 binding was observed for both the DMSO-and TSA-treated cells (Fig. 5A ). Taken together, the results from the EMSAs, the supershift assay and ChIP assay show that Sp1 is recruited to the NATb promoter.
However, the ChIP assay did not suggest that there was an increase in the amount of Sp1 associated with the NATb promoter in vivo. This may be explained by the poor quantitative nature of the ChIP assay, as reported elsewhere (Schroer et al., 2002) . NATb promoter in response to TSA treatment, a ChIP assay was performed using anti-acetylated histone 4 (H4) antibody. No acetylated H4 was associated with NATb in DMSO-treated cells.
However, TSA treatment resulted in recruitment of acetylated H4 to the promoter (Fig. 5B ). This result suggests that the chromatin in the region of the NATb promoter surrounding the Sp1 binding site is hypo-acetylated under normal conditions.
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This article has not been copyedited and formatted. The final version may differ from this version. RNA was isolated, converted to cDNA and NATb transcripts quantified by qPCR. NATb mRNA levels were normalized to β -actin and then expressed relative to T = 0 using the ∆ ∆ CT method.
Linear regression was used to determine the rate of decay of NAT1 mRNA. Data are presented as mean ± SEM (n = 3).
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